Clinical Trials Logo

Filter by:
NCT ID: NCT00267943 Completed - Hypertension Clinical Trials

Open-label Follow-up Trial of Fixed Dose Combination of Telmisartan + Hydrochlorothiazide in Hypertensive Patients

Start date: January 2006
Phase: Phase 3
Study type: Interventional

The primary objective is to assess the efficacy and safety of the fixed dose combination of telmisartan 80 mg + hydrochlorothiazide 25 mg (T80/H25) alone or in addition to other antihypertensive therapies during open-label, long-term treatment.

NCT ID: NCT00266747 Completed - Anxiety Disorders Clinical Trials

An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder

AQUARIUS
Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 700 mg dose of SR58611A compared to placebo in patients with generalized anxiety disorder (GAD).The secondary objectives are to evaluate the efficacy of SR58611A on disability and quality of life in patients with GAD and to evaluate safety of SR58611A.

NCT ID: NCT00264849 Completed - Asthma Clinical Trials

Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma

Start date: November 2005
Phase: Phase 4
Study type: Interventional

Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control. Response to omalizumab over time will be assessed by physicians and patients evaluating the overall improvement in control of their asthma. THIS STUDY IS NOT ENROLLING PATIENTS IN THE US.

NCT ID: NCT00264511 Completed - Tibial Fracture Clinical Trials

Hyperbaric Oxygen in Lower Leg Trauma

Start date: February 13, 2007
Phase: Phase 2/Phase 3
Study type: Interventional

Study hypothesis :Hyperbaric Oxygen may prevent complications and improve outcomes in severe lower limb trauma. We propose to investigate this hypothesis by conducting an International multi centre randomised control trial of standard trauma/orthopaedic care with or without a concurrent course of hyperbaric oxygen treatments.

NCT ID: NCT00263887 Completed - Clinical trials for Alpha 1-Antitrypsin Deficiency

Alpha-1-Antitrypsin (AAT) To Treat Emphysema In AAT-Deficient Patients (EXACTLE)

Start date: December 2003
Phase: Phase 2
Study type: Interventional

The goal of this trial was to explore the utility of evaluating emphysema progression through CT scans measuring lung density during a 2 year period of weekly infusions of either placebo or human alpha-1-antitrypsin (AAT; Prolastin®). Exacerbation data recorded in patient diaries were also collected. All efficacy data were analyzed for potential use in evaluating Prolastin efficacy in this and other clinical trials.

NCT ID: NCT00263718 Completed - Psoriasis Vulgaris Clinical Trials

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Psoriasis Vulgaris

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The objective of the study is to compare the use of calcipotriol plus betamethasone dipropionate gel with betamethasone dipropionate in the gel vehicle, calcipotriol in the gel vehicle and the gel vehicle alone when used in patients with psoriasis vulgaris on the trunk and/or limbs. Patients will be treated once daily for up to 8 weeks. The primary response criterion is the number of patients with controlled disease at week 8.

NCT ID: NCT00263588 Completed - Neoplasms, Breast Clinical Trials

Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer

Start date: December 2, 2005
Phase: Phase 2
Study type: Interventional

Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain radiotherapy) or SRS (stereotactic radiosurgery) to the brain. Lapatinib is an oral drug that will be taken every day. Tests for safety and efficacy will be performed every 4 weeks or 8 weeks (depending on the test) during the course of the study.

NCT ID: NCT00263341 Completed - Contraception Clinical Trials

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The purpose of this 1-year study is to evaluate the efficacy and safety of a new contraceptive vaginal ring (CVR) delivering low doses of Nestorone (NES), a new, nonandrogenic progestin, and ethinyl estradiol (EE), an estrogen used in oral contraceptives. The CVR, which is made of silicone rubber, is designed to be used for 1 year (13 menstrual cycles) before replacement is required.

NCT ID: NCT00263042 Terminated - Clinical trials for Cardiovascular Disease

Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes

CRESCENDO
Start date: December 2005
Phase: Phase 3
Study type: Interventional

The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.

NCT ID: NCT00262600 Completed - Stroke Clinical Trials

Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate

Start date: December 2005
Phase: Phase 3
Study type: Interventional

The primary objective of this trial is to demonstrate the efficacy and safety of dabigatran etexilate in patients with non-valvular atrial fibrillation for the prevention of stroke and systemic embolism.